Production (Stage)
Outlook Therapeutics, Inc.
OTLK
$1.90
$0.031.60%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | 9.66M | 12.52M | 11.20M | -- |
| Gross Profit | -- | -9.66M | -12.52M | -11.20M | -- |
| SG&A Expenses | 7.98M | 11.95M | 10.35M | 8.36M | 5.43M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.39M | 21.61M | 22.88M | 19.56M | 18.94M |
| Operating Income | -12.39M | -21.61M | -22.88M | -19.56M | -18.94M |
| Income Before Tax | -46.35M | 17.38M | 5.69M | 44.41M | -114.29M |
| Income Tax Expenses | 2.80K | -- | 0.00 | -- | 2.80K |
| Earnings from Continuing Operations | -46.36M | 17.38M | 5.69M | 44.41M | -114.29M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.36M | 17.38M | 5.69M | 44.41M | -114.29M |
| EBIT | -12.39M | -21.61M | -22.88M | -19.56M | -18.94M |
| EBITDA | -12.36M | -21.58M | -22.85M | -19.53M | -18.91M |
| EPS Basic | -1.50 | 0.72 | 0.24 | 1.91 | -8.01 |
| Normalized Basic EPS | -0.94 | 0.48 | 0.16 | 0.99 | -2.46 |
| EPS Diluted | -1.50 | 0.72 | 0.24 | -0.89 | -8.01 |
| Normalized Diluted EPS | -0.94 | 0.48 | 0.16 | 0.90 | -2.46 |
| Average Basic Shares Outstanding | 30.87M | 24.23M | 23.73M | 23.23M | 14.27M |
| Average Diluted Shares Outstanding | 30.87M | 24.23M | 23.73M | 25.48M | 14.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |